Author Bio
Rachel primarily covers healthcare stocks for the Fool. She leverages her background and education in the legal field to inform her detailed research and analysis of the stock market.
It s a remarkable time to be an investor. Over the past year, the market has not only recovered its losses from the coronavirus crash, but marked multiple days of new thrilling highs.
The stock market has shown increased volatility in recent weeks. But for the time being, optimism about the U.S. economy s ongoing recovery is outweighing investor concern about the rising rate of inflation. Even so, it s more vital now than ever that investors focus their portfolios on resilient stocks that can continue providing growth and generating consistent returns in a variety of market scenarios.
TrialScope Welcomes Alexion to Its Growing Clinical Trial Disclosure Community prweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prweb.com Daily Mail and Mail on Sunday newspapers.
Innoforce and dMed Collaborate to Accelerate the Development of Innovative Therapeutics
News provided by
Share this article
Share this article
HANGZHOU, China and SHANGHAI, March 2, 2021 /PRNewswire/ Innoforce, a biopharmaceutical innovation enabling platform and PDMO (Partner Development and Manufacturing Organization), and dMed, a clinical CRO with strong presence in China and the US - the world s two largest pharmaceutical and drug development markets, have signed an agreement under which the two parties agreed to establish a partnership to identify, assess, and collaborate on the development of clinical-stage therapeutics.
Dr. Lingshi Tan, founder and CEO of dMed said, Our partnership with Innoforce will provide a powerful avenue to help clinical-stage therapeutic development programs from small and medium companies and to accelerate the pace of clinical development.
4 feb 2021
Skipta Donates Critical Online Media Support to U.S. COVID-19 Vaccine Education Campaign
Contribution will help the Ad Council and COVID Collaborative amplify their national education effort for healthcare professionals in the U.S. around COVID-19 vaccine safety and effectiveness
NEW YORK, Feb. 04, 2021 (GLOBE NEWSWIRE) Skipta, part of Informa Pharma Intelligence and the leading social network of specialized online medical communities for verified healthcare professionals (HCPs), today announced its contribution to the Ad Council and COVID Collaborative’s national COVID-19 vaccine education effort. Skipta will donate in-feed and eNewsletter promotion of educational videos to the initiative to help strengthen vaccine confidence among healthcare providers throughout the United States.
Wednesday, 20 January 2021, 4:03 pm
The year 2021 is set to become quite a year for the
pharma companies leading the COVID-19 vaccine race, with
significant revenues on the line. As some of the most
significant players in the market, pharma giants Pfizer and
Moderna are set for the lion s share of 2021 vaccine
sales.
According to data presented by Finaria.it,
BioNTech-Pfizer and Moderna COVID-19 vaccines sales are
expected to generate $14.7bn in revenue by
2023.
Moderna COVID-19 Vaccine Sales Revenue to hit
$3.5B in 2021
The call for COVID-19 vaccines and
treatments has become louder than ever, with countries
worldwide facing the full force of the pandemic s second